<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3620133</article-id><article-id pub-id-type="publisher-id">1129-2377-14-S1-P191</article-id><article-id pub-id-type="doi">10.1186/1129-2377-14-S1-P191</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Frovatriptan vs other triptans in the treatment of menstrual migraine: pooled analysis of three double-blind, randomized, cross-over studies</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Allais</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Tullo</surname><given-names>V</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Omboni</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Benedetto</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Sances</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Zava</surname><given-names>D</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Ferrari</surname><given-names>MD</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Bussone</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib></contrib-group><aff id="I1"><label>1</label>Department of Gynecology and Obstetrics, Women's Headache Center, University of Torino, Torino, Italy</aff><aff id="I2"><label>2</label>Department of Clinical Neurosciences, Carlo Besta National Neurological Institute, Milano, Italy</aff><aff id="I3"><label>3</label>Italian Institute of Telemedicine, Varese, Italy</aff><aff id="I4"><label>4</label>Headache Centre, IRCCS C. Mondino Foundation, Institute of Neurology, Pavia, Italy</aff><aff id="I5"><label>5</label>Istituto Lusofarmaco d&#x02019;Italia, Milano, Italy</aff><aff id="I6"><label>6</label>Leiden Centre for Translational Neuroscience, Department of Neurology, Leiden University Medical Centre, Netherlands</aff><pub-date pub-type="ppub"><year>2013</year></pub-date><pub-date pub-type="epub"><day>21</day><month>2</month><year>2013</year></pub-date><volume>14</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Abstract Book of The European Headache and Migraine Trust International Congress</named-content><named-content content-type="supplement-editor">Peter J Goadsby and Dominique Valade</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was supported by EHMTIC Limited.</named-content></supplement><fpage>P191</fpage><lpage>P191</lpage><permissions><copyright-statement>Copyright &#x000a9;2013 Allais et al; licensee Springer.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Allais et al; licensee Springer.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.thejournalofheadacheandpain.com/content/14/S1/P191"/><conference><conf-date>20-23 September 2012</conf-date><conf-name>The European Headache and Migraine Trust International Congress</conf-name><conf-loc>London, UK</conf-loc></conference></article-meta></front><body><sec><title>Objective</title><p>To review the efficacy and safety of frovatriptan (F) vs. rizatriptan (R), zolmitriptan (Z) and almotriptan (A), in women with menstrually related migraine (IHS criteria) through a pooled analysis of three individual studies.</p></sec><sec sec-type="methods"><title>Methods</title><p>Subjects with a history of migraine with or without aura were randomized to F 2.5 mg or R 10 mg (study 1), F or Z 2.5 mg (study 2), and F or A 12.5 mg (study 3). The studies had an identical multicenter, randomized, double blind, cross-over design. After treating 3 episodes of migraine in no more than 3 months with the first treatment, patients had to switch to the next treatment for other 3 months.</p></sec><sec sec-type="results"><title>Results</title><p>346 subjects formed the main study intention-to-treat population; 280 of them were of a female gender (81%) and 236 in the fertile age. A total of 187 out of the 236 eligible women (79%) treated at least one episode of menstrual migraine with both medications and were thus included in the present subgroup analysis. Rate of pain free at 2, 4 and 24h was 23%, 52% and 67% with F and 30%, 61% and 66% with comparators (p=NS). Pain relief episodes at 2, 4 and 24h were 37%, 60% and 66% for F and 43%, 55% and 61% for comparators (p=NS). Rate of recurrence was significantly (p&#x0003c;0.05) lower under F either at 24h (11% vs. 24% comparators) or at 48h (15% vs. 26% comparators). Number of menstrual migraine attacks associated with drug-related adverse events was equally low (p=NS) between F (5%) and comparators (4%).</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>According to our analysis of individual studies F is as effective as other triptans in the immediate treatment of menstrual migraine attacks, but exhibits a more sustained effect.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Savi</surname><given-names>L</given-names></name><etal/><source>J Headache Pain</source><year>2011</year><volume>14</volume><fpage>609</fpage><lpage>615</lpage><comment>Allais G et al. Neurol Sci 2011;32(Suppl.1):S99-S104. Bartolini M et al. J Headache Pain 2012;in press</comment><pub-id pub-id-type="doi">10.1007/s10194-011-0366-9</pub-id><pub-id pub-id-type="pmid">21842274</pub-id></mixed-citation></ref></ref-list></back></article>